]

A New Frontier

TB Alliance Annual Report 2018
TREATMENT

Pretomanid Submitted to FDA

Pretomanid, a novel TB drug developed by TB Alliance, is under regulatory review. In December 2018, TB Alliance submitted its first-ever New Drug Application to the U.S. Food and Drug Administration. Pictured: the chemical structure of pretomanid.

Learn more
Access

Improved Childhood TB Medicines Reach 88 Countries

Read more
R&D

Three Late-Stage Clinical Trials Advancing TB Treatment

TB Alliance is working to introduce promising new TB treatments for all forms of the disease. In 2018, we concurrently led three late stage trials – each expected to offer scientific insights that could significantly impact the global epidemic.

Learn more
Partnerships

UN High Level Meeting Sparks Global Commitments to Fight TB

In 2018, the United Nations (UN) held a High-Level Meeting (HLM) on Tuberculosis – only the fifth-ever time the UN devoted an HLM to a health issue.

Read more

TB Alliance in 2018

An overview of TB Alliance's progress in developing new treatment regimens for tuberculosis.

Annual Report 2018